key: cord-0804849-7fvyaih6
authors: Görzer, I.; Buchta, Ch; Chiba, P.; Benka, B.; Camp, J.V.; Holzmann, H.; Puchhammer-Stöckl, E.; Aberle, S.W.
title: First Results of a National External Quality Assessment Scheme for the detection of SARS-CoV-2 genome sequences
date: 2020-07-06
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104537
sha: d54f6eacffc27cf77f764d63aaaaf6e187089ae1
doc_id: 804849
cord_uid: 7fvyaih6

BACKGROUND: Broad and decentralised testing of SARS-CoV-2 RNA genomes is a WHOrecommended strategy to contain the SARS-CoV-2 pandemic by identifying infected cases in order to minimize onward transmission. With the need to increase the test capacities in Austria, nation-wide numerous laboratories rapidly implemented assays for molecular detection of SARSCoV-2 based on real-time RT-PCR assays. The objective of this study was to monitor reliability of the laboratory results for SARS-CoV-2 RNA detection through an external quality assessment (EQA) scheme. METHODS: For this, the Center for Virology, Medical University of Vienna was tasked by the Federal Ministry of Social Affairs, Health, Care and Consumer Protection to perform the first Austrian EQA on SARS-CoV-2 which was organised in cooperation with the Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA). Data were analysed on the basis of qualitative outcome of testing in relation to the nucleic acid (NA) extraction and detection methods used. RESULTS AND CONCLUSION: A total of 52 laboratories participated, contributing results from 67 test panels comprising 42 distinct combinations of NA extraction and PCR reagents. By testing 3 positive (CT values: S1, 28.4; S2, 33.6; S3, 38.5) and 1 negative sample, no false-positive results were obtained by any of the laboratories. Otherwise, 40/67 tests (60%) detected all positive samples correctly as positive, but 25/67 tests (37%) did not detect the weakest positive sample (S3), and 3% reported S2 and S3 as falsenegative. Improvement in test sensitivity by focusing on NA extraction and/or PCR-based detection is recommended.

and Public Health England, London (UK) [3] . Reagents were made available through TIB Molbiol Berlin (Germany). Numerous other companies followed with similar PCR-based approaches and the World Health Organization (WHO) as well as the European Centre for Disease Prevention and Control (ECDC) provided a list of available laboratory tests for the molecular detection of SARS-CoV-2. In addition, online guidance to allow promoting the implementation of diagnostic protocols in laboratories other than expert laboratories was provided.

The initial WHO strategy recommended containment of SARS-CoV-2 by rapidly identifying cases and by tracing contact cases in order to minimize onward transmission [4]. This required broad and decentralised screening and the rapid increase in test capacities. Hence, in Austria many laboratories nation-wide began introducing SARS-CoV-2 molecular detection assays.

Reliable laboratory results are essential for rapid and accurate decision making in patient care [5] . In addition to internal quality control, participation in an External Quality Assessment The objectives of this first EQA scheme were to assess the capability of individual laboratories to perform sensitive and reliable SARS-CoV-2 molecular diagnostics and to provide insights into the limits of test sensitivity in order to improve SARS-CoV-2 RNA detection capabilities.

The EQA test panel consisted of four samples (900µl each), three positive and one negative, that were distributed by the Center for Virology to participant laboratories. Positive samples were three individual SARS-CoV-2 positive oro-nasopharyngeal swab samples 100-fold diluted with sterile sodium chloride solution (0.9% NaCl). The negative sample consisted of the diluent, a 0.9% NaCl solution. In order to guarantee stability of SARS-CoV-2 genomic RNA, all samples were stored at -20°C and one panel was tested before shipment as follows:

after thawing, samples were kept at ambient temperature for 2 days (anticipated maximum shipping time) before further storage at 4°C for 4 days (maximal expected storage time before testing). Thereafter, samples were quantified with our in-house SARS-CoV-2 molecular detection assay. For this, nucleic acid (NA) was extracted from 200µl input sample and eluted in 50µl of elution buffer using the NucliSENS easyMAG platform (bioMérieux, France). For The final cycle threshold (CT) values of the three positive samples were: 28.4 (S1), 33.6 (S2), 38.5 (S3) for the E-gene of the SARS-CoV-2 genome. The sample S4 was negative as expected.

A questionnaire for participation was sent out at the beginning of May to 82 laboratories in Austria known to have implemented molecular tests for detection of SARS-CoV-2 RNA genomes. Therein, laboratories were informed about the EQA scheme and in terms of participation the laboratories were asked to provide information about the implemented test systems including NA extraction platform and reagents for real-time RT-PCR. Samples were dispatched on May 18 by overnight-express delivery at ambient temperature conditions and participants were instructed to either immediately test or alternatively store the material at 4°C until analysis and to perform testing in the same way as routine samples. Individual laboratories which intended to participate with more than one molecular test system received independently shipped test panels for each test system.

Raw data and qualitative interpretation (positive, negative) were submitted to the EQA provider with a deadline of May 26 via a web portal, email, fax or paper. Individual results were scored as either correct or incorrect and summarised in a general report in addition to individual reports. Optionally, the participants had the possibility to report the target region(s) of the respective real-time RT-PCR assays and obtain CT or Cq values reported by all laboratories.

J o u r n a l P r e -p r o o f Fifty-two laboratories participated with a total of 67 test panels. Forty-two laboratories participated with one and 10 laboratories with more than one test panel. In particular, 6/10 laboratories used two, three labs used three, and one lab used four distinct test systems. All laboratories responded in time and their results were submitted along with the raw data.

The negative sample S4 tested negative in all 67 individual panels (100%). Otherwise, 40/67 test systems (59.7 %) detected all three positive samples as positive, 25/67 tests (37.3 %) found S3 (CT value of E-gene, 38.5) as negative, and 2/67 (3 %), found the S2 (CT value of E-gene, 33.6) and S3 as negative ( Table 1) .

Analysis of data at the laboratory level showed that 34 labs (65.4 %) detected all samples correctly with at least one test system. S3 was incorrectly reported negative by 17/52 labs (32.7 %), and 1/52 labs (1.9 %) reported false-negative for samples S2 and S3.

Of the ten labs that used more than one test system, six labs reported identical (consistent) results for all systems and four labs reported contradictory results for the different test

A total of 27 different NA extraction platforms were used including 6 fully-or semi-automated platforms with a combined NA extraction and amplification workflow (GeneXpert, Cobas 6800, BD Max, NeuMoDX, GenomEra, and AIGS), 15 semi-automatic NA extraction or pipetting platforms, and at least 5 distinct column-based NA isolation kits either manually or semi-automatically applied. The data are shown in Table 3 . Notably, two platforms, GeneXpert and Cobas 6800, were used by 12 distinct centers and none of these reported false-negative results (Table 3 ).

In terms of real-time RT-PCR reagents, 22 distinct assays were used (Table 4 ). The most frequently used reagent kits were from RealStar (Altona), ViroReal (Ingenetix), Xpert Xpress (Cepheid) and LightMix Modular (TIB Molbiol).

For the platforms GeneXpert, Cobas 6800, GenomEra, and AIGS the PCR reagents were used as recommended by the company. The remaining 18 distinct PCR assays were independently combined with 22 types of NA extraction, resulting in an overall of at least 38 distinct test systems. The outcomes are shown in Table 5 .

Finally, the participating laboratories had the possibility to report the target region(s) along with the achieved CT or Cq values of the respective PCR assays. The reported target regions were within the E-gene, N-gene, RdRP-gene, and S-gene, listed in order from most used to least. The best test performances (% correctly detected samples) were reported for assays targeting the Egene as given in Table 6 and Figure 1 .

Of the 52 laboratories that participated in the EQA for molecular SARS-CoV-2 genome testing, 65% achieved the maximum score possible, meaning that all 4 samples were reported correctly.

Although none of the participating laboratories reported a false-positive result, 35% of the laboratories did not detect the SARS-CoV-2 genome in sample S3 which had the lowest concentration (CT 38.5) of the 3 positive EQA test samples. A decrease in SARS-CoV-2 RNA in sample S3 during shipment is considered unlikely, as the stability of the viral RNA in the test panels was tested before dispatch under shipment conditions. In addition, shipment day and delivery time of the test panels was identical for all participants and no significant difference in J o u r n a l P r e -p r o o f the time of analysis was observed between the group which correctly analysed S3 as positive and that which tested S3 false-negative (p = 0.56; unpaired t-test). The observation that all except one laboratory detected sample S2 correctly, which had the second lowest concentration (CT 33.6), suggests that the sensitivity limit of the respective test systems may conform to viral loads between S2 and S3. To further clarify this point, a positive sample with a viral load between S2 and S3 will be included in future quality assessment rounds for SARS-CoV-2 genome testing.

Since numerous different real-time RT-PCR assays combined with a variety of different methods for NA extraction were used, no clear evidence for a substantial advantage of one system over another can be observed. Clearly, the best test performance was achieved for the fully automated test systems GeneXpert and Cobas 6800, which all detected the low positive sample S3. The high sensitivity of these two test systems is likely due to the high amount of input material for NA extraction combined with a high volume of extracted NA used for the SARS-CoV-2 genome detection. We obtained volumes for the NA extraction and real-time RT-PCR steps for other test systems and did not find a statistically significant difference between the group that identified sample S3 as positive and the group which failed to report a positive result (1: S3 correct, n = 20; 2: S3 false-negative, n = 16; p = 0.69; unpaired t-test). Nevertheless, high dilution in the NA extraction step and use of small aliquots of the extract in the RT-PCR Overall, most laboratories achieved reasonable test sensitivity, which is an important prerequisite for early detection of viral spread. Nevertheless, test sensitivity can be improved by a modification of the workflow, for example by modifying volumes in the NA extraction method and/or the volume used in the RT-PCR step. An increase in analytical sensitivity may also be critical when considering pooling [7] .

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. J o u r n a l P r e -p r o o f 

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

We gratefully thank Tanja Amon, Andreas Rohorzka, and Ursula Sinzinger for excellent technical assistance.

The Authors have no conflicts of interest to declare.